title: Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
abstract: Because the most characteristic property of ovarian cancer is i.p. spread, the majority of patients are diagnosed at an advanced stage, leading to limited availability of options for curative therapies. With an intent to identify targeted therapeutic approaches, we have observed that approximately 60% of 21 ovarian cancer tissue samples express a high density of interleukin-4 receptor (IL-4R), whereas normal ovarian tissues tested (n = 7) expressed no or low levels of IL-4R. To target IL-4R, we have developed IL-4 cytotoxin, in which circular-permuted IL-4 is fused to a mutated form of Pseudomonas exotoxin. This cytotoxin is specifically and highly cytotoxic to PA-1, IGROV-1, and SK-OV3 ovarian carcinoma cell lines in vitro. In addition, it shows remarkable antitumor activities against established s.c. ovarian tumors in immunodeficient animals. i.p. administration of IL-4 cytotoxin in mice with orthotopically implanted ovarian tumors caused regression of established tumors and prevented these animals from tumor metastasis. Continuous i.p. infusion of IL-4 cytotoxin prolonged survival of tumor-bearing mice even with bulky disease. These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the management of patients with ovarian cancer, and further studies need to be done to evaluate its safety, tolerability, and efficacy.
authors.affiliation: Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.
authors.forename: Mitomu
authors.initials: M
authors.lastname: Kioi
authors.forename: Satoru
authors.initials: S
authors.lastname: Takahashi
authors.forename: Mariko
authors.initials: M
authors.lastname: Kawakami
authors.forename: Koji
authors.initials: K
authors.lastname: Kawakami
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Kreitman
authors.forename: Raj K
authors.initials: RK
authors.lastname: Puri
mesh_terms: D000818:Animals; D002100:Cachexia / Q000517:prevention & control; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D005098:Exotoxins / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D019948:Receptors, Interleukin-4 / Q000096:biosynthesis / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D005098:Exotoxins; C059989:IL-4-PE40 protein, recombinant; D019948:Receptors, Interleukin-4; D011993:Recombinant Fusion Proteins; D015847:Interleukin-4